Preprint up from our friends in Newcastle.
Upregulated cholesterol biosynthesis facilitates the survival of methylation-retaining AML cells following decitabine treatment.
https://www.biorxiv.org/content/10.1101/2024.01.30.577864v1
Competing Interests
A.K.E. declares the following competing interests: Advisory board/ Honoraria from AbbVie, Astellas, Gilead, Servier, Jazz, Otsuka/Astex and RACE Oncology; Speakers fees from AbbVie, Otsuka/Astex, Astellas and Jazz; Research Funding from RACE Oncology and Otsuka/Astex.
General Comments / Chat, page-10399
-
- There are more pages in this discussion • 869 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.44 |
Change
0.040(2.86%) |
Mkt cap ! $245.3M | |||
| Open | High | Low | Value | Volume |
| $1.45 | $1.49 | $1.41 | $101.7K | 69.88K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9216 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.47 | 7767 | 2 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |